Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter August 21, 2014

Evaluation of a new thyroglobulin sensitive assay in patients with differentiated thyroid cancer

Marie-Hélène Schlageter ORCID logo, Marie-Elisabeth Toubert, Taly Meas, Esther Bouhassira, Isabelle Faugeron, Virginie Vimont, Eddy Thomas, Christian Theimer and Christine Chomienne

Corresponding author: Marie-Hélène Schlageter, Service de Biologie Cellulaire, Hôpital Saint-Louis, AP-HP, 1 Avenue Claude Vellefaux, 75010, Paris, France, Phone: +33 1 42499404, Fax: +33 1 42385476, E-mail: .

References

1. Pacini F, Castagna MG, Brilli L, Pentheroudakis G, on behalf of the ESMO Guidelines Working Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:110–9.10.1093/annonc/mds230Search in Google Scholar PubMed

2. Giovanella L, Clark PM, Chiovato L, Duntas L, Elisei R, Feldt-Rasmussen U, et al. Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. Eur J Endocrinol 2014;171:R33–46.10.1530/EJE-14-0148Search in Google Scholar PubMed PubMed Central

3. Giovanella L, Treglia G, Sadeghi R, Trimboli P, Ceriani L, Verburg FA. Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta- analysis. J Clin Endocrinol Metab 2014;99:440–7.10.1210/jc.2013-3156Search in Google Scholar PubMed

4. Malandrino P, Latina A, Marescalco S, Spadaro A, Regalbuto C, Fulco RA, et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab 2011;96:1703–9.10.1210/jc.2010-2695Search in Google Scholar PubMed

5. Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 2011;96:1352–9.10.1210/jc.2010-2708Search in Google Scholar PubMed

6. Chindris AM, Diehl NN, Crook JE, Fatourechi V, Smallridge RC. Undetectable sensitive serum thyroglobulin (<0.1 ng/mL) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. J Clin Endocrinol Metab 2012;97:2714–23.10.1210/jc.2011-3017Search in Google Scholar PubMed

7. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1169–214.10.1089/thy.2009.0110Search in Google Scholar PubMed

8. Spencer C, Fatemi S. Thyroglobulin antibody (TgAb) methods – strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. Best Practice Res Clin Endocrinol Metab 2013;27:701–12.10.1016/j.beem.2013.07.003Search in Google Scholar PubMed

9. Verburg FA, Luster M, Cupini C, Chiovato L, Duntas L, Elisei R, et al. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. Thyroid 2013;23:1211–25.10.1089/thy.2012.0606Search in Google Scholar PubMed

10. Massart C, Corcuff JB, Bordenave L. False-positive results corrected by the use of heterophilic antibody-blocking reagent in thyroglobulin immunoassays. Clin Chim Acta 2008;388:211–3.10.1016/j.cca.2007.09.024Search in Google Scholar PubMed

Received: 2014-6-24
Accepted: 2014-7-22
Published Online: 2014-8-21
Published in Print: 2015-2-1

©2015 by De Gruyter

Scroll Up Arrow